Clinical trials

Melbourne-linked biopharmaceutical company Azura Ophthalmics has announced positive results from a Phase 2 clinical trial of its investigational dry eye...

Clinical trials innovator and digital health expert Ms Michelle Gallaher has been appointed the inaugural CEO of Cerulea, a new...

A $2.9 million funding injection from the Federal Government will support the rollout of a new saliva-based genetic test for...

Apellis Pharmaceuticals has responded to “positive” 24-month data for its pioneering geographic atrophy (GA) therapy published in The Lancet, demonstrating...

Astellas Pharma has announced positive 24-month topline results from the GATHER2 Phase 3 clinical study of IZERVAY, developed by its...

Novartis will discontinue development of GT005 gene therapy, a subretinal injection for geographic atrophy (GA), in a blow to the...

The US FDA has approved the use of high dose Eylea (aflibercept) for three macular conditions, equating to longer intravitreal...

Melbourne biotech company muPharma, founded by ophthalmologist Dr Harry Unger and Mr Mark Unger, has developed an investigational device that...

Much effort is going into understanding the impact of combined treatments for myopia management, but little is known about the...

US biopharmaceutical company Iveric Bio has released new data for its avacincaptad pegol (ACP) therapy for geographic atrophy (GA), which...